Nykredit A S Buys New Shares in AbbVie Inc. $ABBV

Key Points

• Nykredit A/S acquired 596,240 AbbVie shares during the second quarter, worth approximately $150 million. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie exceeded quarterly expectations, reporting $3.65 in EPS and $16.99 billion in revenue, with revenue up 10.2% year over year. The company also declared a quarterly dividend of $1.73 per share, yielding about 2.6% annually.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $276.64. However, the stock’s elevated valuation and reliance on continued Skyrizi growth remain key risks.

Nykredit A S bought a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 596,240 shares of the company's stock, valued at approximately $150,038,000.

Several other large investors have also recently bought and sold shares of ABBV. Parkside Financial Bank & Trust lifted its position in shares of AbbVie by 2.2% in the second quarter. Parkside Financial Bank & Trust now owns 29,261 shares of the company's stock valued at $7,363,000 after buying an additional 630 shares during the last quarter. Kinetic Wealth Investment Advisors LLC acquired a new stake in AbbVie during the 2nd quarter valued at $298,000. Range Advisory LLC boosted its position in AbbVie by 88.9% during the second quarter. Range Advisory LLC now owns 5,721 shares of the company's stock worth $1,440,000 after purchasing an additional 2,692 shares during the period. Capital & Planning LLC increased its holdings in shares of AbbVie by 21.5% in the second quarter. Capital & Planning LLC now owns 19,416 shares of the company's stock valued at $4,886,000 after purchasing an additional 3,430 shares during the last quarter. Finally, Brown Lisle Cummings Inc. increased its holdings in shares of AbbVie by 0.5% in the second quarter. Brown Lisle Cummings Inc. now owns 28,996 shares of the company's stock valued at $7,296,000 after purchasing an additional 139 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Up 0.6%

ABBV stock opened at $264.03 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The business has a 50-day simple moving average of $255.24 and a 200 day simple moving average of $231.94. The company has a market cap of $466.48 billion, a PE ratio of 74.58, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie's dividend payout ratio is presently 195.48%.

Analysts Set New Price Targets

ABBV has been the subject of a number of research reports. Royal Bank Of Canada raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, July 10th. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. JPMorgan Chase & Co. upped their target price on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. Finally, Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $276.64.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple myeloma pipeline delivers encouraging results: AbbVie said the Phase 3 CERVINO trial of investigational etentamig met both primary endpoints—objective response rate and progression-free survival—in relapsed or refractory multiple myeloma. The reported 74% response rate and upcoming detailed presentation at the International Myeloma Society meeting strengthen expectations for a potential future growth driver. AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio
• Positive Sentiment: Broader oncology strategy: Additional data on ABBV-2001, surzetoclax and combination therapies support AbbVie’s effort to build a diversified multiple myeloma portfolio across different treatment mechanisms. AbbVie To Present Positive Phase 3 Etentamig Data At IMS 2026
• Positive Sentiment: Neuroscience growth remains a support: AbbVie’s expanded portfolio in psychiatry, migraine and Parkinson’s treatments is described as a contributor to strong growth and a higher 2026 outlook. Cantor Fitzgerald also reiterated an Overweight rating, citing the promise of zumilokibart. How AbbVie’s Neuroscience Portfolio Has Transformed Over the Years
• Positive Sentiment: Aesthetics business finds a new opportunity: Allergan Aesthetics reported statistically significant improvements from targeted skincare regimens and DiamondGlow treatments for people taking medical weight-loss medications, potentially supporting demand in its aesthetics business. Allergan Aesthetics Presents New Clinical Data
• Neutral Sentiment: Valuation is increasingly important: AbbVie has gained roughly 24% over the past year and is near its 52-week high. Some commentary views the shares as undervalued based on future cash flow, while the elevated valuation leaves less room for disappointing results. AbbVie Stock Looks Undervalued On Future Cash Flow
• Negative Sentiment: Dependence on Skyrizi creates risk: The investment case relies heavily on Skyrizi continuing to grow more than 20% annually while older medicines decline. Any slowdown could pressure earnings expectations and the stock’s premium valuation. What Happens To AbbVie Stock If SKYRIZI Slows Down?

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.